The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer

Cohort 1: Inclusion Criteria: 1. Age ≥ 18 years old; 2. Histologically confirmed diagnosis of NSCLC; 3. Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition; 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1; 5. Treatment naïve; 6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1); 7. Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy; 8. Informed consent to participate in the study; Exclusion Criteria: 1. Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) fusion and/or ROS proto-oncogene 1 (ROS1) fusion-positive; 2. Presence of other malignant tumors or malignant diseases within 3 years; 3. Concurrent acute or chronic psychiatric disorders; 4. Patients receiving sleep medication; 5. Prior participation in other clinical drug trials; 6. Symptomatic brain metastasis; 7. Inability to complete scale assessments. Cohort 2: Inclusion Criteria: 1. Age ≥ 18 years old; 2. Histologically confirmed diagnosis of SCLC； 3. Unresectable locally advanced, metastatic, or recurrent stage Ⅲ-Ⅳ based on AJCC TNM staging 8th edition; 4. ECOG PS of 0-1; 5. Treatment naïve; 6. Presence of at least one measurable lesion according to the RECIST v1.1 ; 7. Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy; 8. Informed consent to participate in the study; Exclusion Criteria: 1. Presence of other malignant tumors or malignant diseases within 3 years; 2. Concurrent acute or chronic psychiatric disorders; 3. Patients receiving sleep medication; 4. Prior participation in other clinical drug trials; 5. Symptomatic brain metastasis; 6. Inability to complete scale assessments. Cohort 3: Inclusion Criteria: 1. Age ≥18 years old; 2. Pathologically diagnosed as NSCLC; 3. Resectable clinical stage IB-IIIB based on AJCC TNM staging 8th edition; 4. At least one measurable lesion can be evaluated according to the RECIST v1.1; 5. Treatment naïve; 6. Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy as neoadjuvant therapy; 7. Cardiopulmonary function can withstand surgery; 8. Informed consent to participate in the study. Exclusion Criteria: 1. EGFR-sensitizing mutation and/or ALK fusion and/or ROS1 fusion-positive; 2. Presence of other malignant tumors or malignant diseases within 3 years; 3. Concurrent acute or chronic psychiatric disorders; 4. Patients receiving sleep medication; 5. Prior participation in other clinical drug trials; 6. Symptomatic brain metastasis; 7. Inability to complete scale assessments. Cohort 4: Inclusion Criteria: 1. Age ≥ 18 years old; 2. Pathologically diagnosed as NSCLC; 3. Pathologically stage confirmed as early stage of IA-IIIA; 4. Available for tumor tissue samples; 5. Treatment naïve; 6. Receiving radical surgery; 7. Informed consent to participate in the study; Exclusion Criteria: 1. Presence of other malignant tumors or malignant diseases within 3 years; 2. Concurrent acute or chronic psychiatric disorders; 3. Patients receiving sleep medication; 4. Prior participation in other clinical drug trials; 5. Inability to complete scale assessments. Cohort 5: Inclusion Criteria: 1. Age ≥ 18 years old; 2. Histologically confirmed diagnosis of NSCLC; 3. Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition; 4. ECOG PS of 0-1; 5. Treatment naive; 6. Presence of at least one measurable lesion according to the RECIST v1.1; 7. Receiving targeted therapy or combination with chemotherapy; 8. Informed consent to participate in the study; 9. Driver gene-positive. Exclusion Criteria: 1. Presence of other malignant tumors or malignant diseases within 3 years; 2. Concurrent acute or chronic psychiatric disorders; 3. Patients receiving sleep medication; 4. Prior participation in other clinical drug trials; 5. Symptomatic brain metastasis; 6. Inability to complete scale assessments.